カテゴリ： Allied Market Research, 世界, 医療/バイオ

慢性B型肝炎（CHB）のグローバル市場（2021〜2031）：抗ウイルス薬、免疫調節薬

■ 英語タイトル：Chronic Hepatitis B (CHB) Market By Drug Class (Antivirals, Immune Modulators), By Gender (Male, Female), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB203）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB203
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：290
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[慢性B型肝炎（CHB）のグローバル市場（2021〜2031）：抗ウイルス薬、免疫調節薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に4,589.8百万ドルであった世界の慢性B型肝炎（CHB）市場規模が、2031年までに6,213.15百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）3.0%で成長すると予測しています。本レポートは、慢性B型肝炎（CHB）の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、薬物クラス別（抗ウイルス薬、免疫調節薬）分析、性別（男性、女性）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン提供者）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、GlaxoSmithKline (GSK)、Gilead Sciences, Inc.、Merck & Co. Inc.、Bristol Myers Squibb Co.、Teva Pharmaceutical Industries Limited、zydus cadila、Novartis AGなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の慢性B型肝炎（CHB）市場規模：薬物クラス別
- 抗ウイルス薬における市場規模
- 免疫調節薬における市場規模
・世界の慢性B型肝炎（CHB）市場規模：性別
- 男性における市場規模
- 女性における市場規模
・世界の慢性B型肝炎（CHB）市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン提供者チャネルの市場規模
・世界の慢性B型肝炎（CHB）市場規模：地域別
- 北米の慢性B型肝炎（CHB）市場規模
- ヨーロッパの慢性B型肝炎（CHB）市場規模
- アジア太平洋の慢性B型肝炎（CHB）市場規模
- 中南米・中東・アフリカの慢性B型肝炎（CHB）市場規模
・企業状況
・企業情報

慢性B型肝炎（CHB）の世界市場規模は2021年に45億8,980万ドル、2031年には62億1,315万ドルに達すると予測され、2022年から2031年までの年平均成長率は3.0%となる見込みです。
B型肝炎は肝臓を攻撃するウイルス感染症であり、急性疾患と慢性疾患の両方を引き起こす可能性があります。B型肝炎は、B型肝炎ウイルス（HBV）によって引き起こされる、生命を脅かす可能性のある肝臓感染症です。B型肝炎は慢性感染を引き起こし、肝硬変や肝臓がんによる死亡リスクを高めます。

B型肝炎の罹患率の増加とB型肝炎に対する意識の高まりが市場の成長を後押ししています。例えば、2022年6月に発表された世界保健機関（WHO）の報告書によると、世界全体では2019年に推定2億9600万人が慢性B型肝炎（CHB）に感染して生活しており、毎年150万人が新たに感染しています。したがって、世界的なB型肝炎の有病率の増加が市場の成長を後押しします。

さらに、献血の増加や輸血率の上昇といった要因も市場の成長を促進します。輸血はB型肝炎ウイルス感染の主な原因です。例えば、2022年5月に発表された世界保健機関（WHO）の報告書によると、世界中で約1億1854万件の献血が行われています。このうち約40％は高所得国で集められています。世界保健機関（WHO）は、すべての献血について、使用前に感染症のスクリーニングを行うことを推奨しています。HIV、B型肝炎、C型肝炎、梅毒のスクリーニングを義務付けるべきです。

さらに、新規慢性B型肝炎（CHB）治療薬開発のための研究開発活動の増加、米国食品医薬品局（FDA）の承認取得の増加、主要企業による新規製品の市場投入が市場の成長を後押しします。例えば、2022年6月、サイエンス主導のグローバルヘルスケア企業であるglaxosmithkline（GSK）は、慢性B型肝炎（CHB）患者における24週間の治療後、B型肝炎表面抗原（HBsAg）とB型肝炎ウイルス（HBV）DNAのレベルを低下させたことを示す、B型肝炎のための治験用アンチセンスオリゴヌクレオチド治療薬であるベピロビルセン（bepirovirsen）のB-Clear第IIb相試験の中間結果を発表しました。さらに、B型肝炎治療の進歩や診断率の上昇も市場成長に寄与しています。しかし、慢性B型肝炎（CHB）治療薬の高価格が市場成長の妨げになると予測されています。

慢性B型肝炎（CHB）市場は薬剤クラス、性別、流通チャネル、地域によって区分されます。薬剤クラス別では、市場は抗ウイルス薬と免疫調整薬に分類されます。性別では、市場は男性と女性に分類されます。男性セグメントはさらに成人と高齢者に分けられます。女性セグメントもさらに成人と高齢者に分けられます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAに市場を分けて分析しています。

本レポートに掲載されている主要企業は、Biocon Inc、Cipla Limited、Dr. Reddy’s Laboratories、Gilead Sciences, Inc、Novartis AG、Reliance Life Sciences、Sun Pharmaceutical Industries Limited、Teva pharmaceuticals、Viatris Inc、Zydus Cadilaなどです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの慢性B型肝炎（CHB）市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、慢性B型肝炎（CHB）市場の有力な市場機会を特定します。
・市場調査は主要な促進要因、阻害要因、機会に関する情報とともに提供されます。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・慢性B型肝炎（CHB）市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を、世界市場に対する収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・慢性B型肝炎（CHB）の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を収録しています。

〈主要市場セグメント〉
薬剤クラス別
抗ウイルス薬
免疫調節薬

性別
男性
女性

販売チャネル別
病院薬局
ドラッグストア・薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
GlaxoSmithKline (GSK)
Gilead Sciences, Inc.
Merck & Co. Inc.
Bristol Myers Squibb Co.
Teva Pharmaceutical Industries Limited
zydus cadila
Novartis AG
F. Hoffman La Roche, Ltd.
Viatris Inc. (Mylan NV)
Cipla Ltd

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Antivirals
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Immune Modulators
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER
5.1 Overview
5.1.1 Market size and forecast
5.2 Male
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Male Chronic Hepatitis B (CHB) Market by Age Group
5.2.4.1 Adult Market size and forecast, by region
5.2.4.2 Geriartic Market size and forecast, by region
5.3 Female
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.3.4 Female Chronic Hepatitis B (CHB) Market by Age Group
5.3.4.1 Adult Market size and forecast, by region
5.3.4.2 Geriartic Market size and forecast, by region
CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Gender
7.2.3.1 North America Male Chronic Hepatitis B (CHB) Market by Age Group
7.2.3.2 North America Female Chronic Hepatitis B (CHB) Market by Age Group
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Gender
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Gender
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Gender
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Gender
7.3.3.1 Europe Male Chronic Hepatitis B (CHB) Market by Age Group
7.3.3.2 Europe Female Chronic Hepatitis B (CHB) Market by Age Group
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Gender
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Gender
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Gender
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Gender
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Gender
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Gender
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Gender
7.4.3.1 Asia-Pacific Male Chronic Hepatitis B (CHB) Market by Age Group
7.4.3.2 Asia-Pacific Female Chronic Hepatitis B (CHB) Market by Age Group
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Gender
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Gender
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Gender
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Gender
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Gender
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Gender
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Gender
7.5.3.1 LAMEA Male Chronic Hepatitis B (CHB) Market by Age Group
7.5.3.2 LAMEA Female Chronic Hepatitis B (CHB) Market by Age Group
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Gender
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Gender
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Gender
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Gender
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 GlaxoSmithKline (GSK)
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Gilead Sciences, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Merck & Co. Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bristol Myers Squibb Co.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Teva Pharmaceutical Industries Limited
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 zydus cadila
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 F. Hoffman La Roche, Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Viatris Inc. (Mylan NV)
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Cipla Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. CHRONIC HEPATITIS B (CHB) MARKET, FOR ANTIVIRALS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. CHRONIC HEPATITIS B (CHB) MARKET FOR ANTIVIRALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. CHRONIC HEPATITIS B (CHB) MARKET, FOR IMMUNE MODULATORS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. CHRONIC HEPATITIS B (CHB) MARKET FOR IMMUNE MODULATORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 7. CHRONIC HEPATITIS B (CHB) MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
TABLE 8. CHRONIC HEPATITIS B (CHB) MARKET FOR MALE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. GLOBAL MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 10. CHRONIC HEPATITIS B (CHB) MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 11. CHRONIC HEPATITIS B (CHB) MARKET, FOR GERIARTIC, BY REGION, 2021-2031 ($MILLION)
TABLE 12. CHRONIC HEPATITIS B (CHB) MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
TABLE 13. CHRONIC HEPATITIS B (CHB) MARKET FOR FEMALE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 15. CHRONIC HEPATITIS B (CHB) MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 16. CHRONIC HEPATITIS B (CHB) MARKET, FOR GERIARTIC, BY REGION, 2021-2031 ($MILLION)
TABLE 17. GLOBAL CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 18. CHRONIC HEPATITIS B (CHB) MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 19. CHRONIC HEPATITIS B (CHB) MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. CHRONIC HEPATITIS B (CHB) MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 21. CHRONIC HEPATITIS B (CHB) MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. CHRONIC HEPATITIS B (CHB) MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. CHRONIC HEPATITIS B (CHB) MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. CHRONIC HEPATITIS B (CHB) MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 32. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 33. U.S. CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 36. CANADA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 39. MEXICO CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 42. EUROPE MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 43. EUROPE FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 44. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 45. EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 46. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 48. GERMANY CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 51. FRANCE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. UK CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. UK CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 54. UK CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 57. ITALY CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 60. SPAIN CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 70. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 71. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 72. JAPAN CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 74. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 75. CHINA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 76. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 77. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 79. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 80. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 81. INDIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 88. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 89. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 90. LAMEA MALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 91. LAMEA FEMALE CHRONIC HEPATITIS B (CHB) MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 92. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 94. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 95. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 96. BRAZIL CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 106.GLAXOSMITHKLINE (GSK): COMPANY SNAPSHOT
TABLE 107.GLAXOSMITHKLINE (GSK): OPERATING SEGMENTS
TABLE 108.GLAXOSMITHKLINE (GSK): PRODUCT PORTFOLIO
TABLE 109.GLAXOSMITHKLINE (GSK): NET SALES,
TABLE 110.GLAXOSMITHKLINE (GSK): KEY STRATERGIES
TABLE 111.GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 112.GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 113.GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 114.GILEAD SCIENCES, INC.: NET SALES,
TABLE 115.GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 116.MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 117.MERCK & CO. INC.: OPERATING SEGMENTS
TABLE 118.MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 119.MERCK & CO. INC.: NET SALES,
TABLE 120.MERCK & CO. INC.: KEY STRATERGIES
TABLE 121.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT
TABLE 122.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS
TABLE 123.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO
TABLE 124.BRISTOL MYERS SQUIBB CO.: NET SALES,
TABLE 125.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES
TABLE 126.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 127.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
TABLE 128.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES,
TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 131.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 132.ZYDUS CADILA: OPERATING SEGMENTS
TABLE 133.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 134.ZYDUS CADILA: NET SALES,
TABLE 135.ZYDUS CADILA: KEY STRATERGIES
TABLE 136.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 137.NOVARTIS AG: OPERATING SEGMENTS
TABLE 138.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 139.NOVARTIS AG: NET SALES,
TABLE 140.NOVARTIS AG: KEY STRATERGIES
TABLE 141.F. HOFFMAN LA ROCHE, LTD.: COMPANY SNAPSHOT
TABLE 142.F. HOFFMAN LA ROCHE, LTD.: OPERATING SEGMENTS
TABLE 143.F. HOFFMAN LA ROCHE, LTD.: PRODUCT PORTFOLIO
TABLE 144.F. HOFFMAN LA ROCHE, LTD.: NET SALES,
TABLE 145.F. HOFFMAN LA ROCHE, LTD.: KEY STRATERGIES
TABLE 146.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT
TABLE 147.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS
TABLE 148.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO
TABLE 149.VIATRIS INC. (MYLAN NV): NET SALES,
TABLE 150.VIATRIS INC. (MYLAN NV): KEY STRATERGIES
TABLE 151.CIPLA LTD: COMPANY SNAPSHOT
TABLE 152.CIPLA LTD: OPERATING SEGMENTS
TABLE 153.CIPLA LTD: PRODUCT PORTFOLIO
TABLE 154.CIPLA LTD: NET SALES,
TABLE 155.CIPLA LTD: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 治療薬物モニタリング（TDM）のグローバル市場（2021-2031）：消耗品、装置
  • 胃がん のグローバル市場（2021-2031）：腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他
  • ダーマルフィラー（皮膚充填剤）のグローバル市場（2021〜2031）：ヒアルロン酸（HA）、カルシウムヒドロキシルアパタイト（CaHA）、ポリL乳酸、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB203 )"慢性B型肝炎（CHB）のグローバル市場（2021〜2031）：抗ウイルス薬、免疫調節薬" (英文：Chronic Hepatitis B (CHB) Market By Drug Class (Antivirals, Immune Modulators), By Gender (Male, Female), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。